THE STUDY
Randomised, double-blind trial of three treatment regimens. 
STUDY SETTING

PARTICIPANTS
Included:
HIV-1 positive pregnant women participating in the national program of voluntary counselling and testing who were receiving Zidovudine prophylaxis (starting at 28 weeks gestation or as soon as possible thereafter) at any of the 37 study sites in Thailand. The patients must have received Zidovudine for at least two weeks, signed informed consent, agreed not to breast feed, and lab values of: haemoglobin > 8.0g/dl; absolute neutrophil count > 750 cells/mm 3 ; alanine aminotransferase level < 35 U/l; creatine level < 1.5mg/dl.
Excluded:
Maternal of fetal condition; concommittant treatment that contraindicated treatment with Zidovudine or Nevirapine, oligohydramnois; unexplained polyhydramnois or in utero anaemia; medical condition that required immediate use of highly active antiretroviral therapy.
INTERVENTION
Standard Zidovudine prophylaxis treatment regime:
All women received 300mg Zidovudine twice daily starting at 28 weeks gestation or as soon as possible thereafter. The dosing regime was changed to 300mg every three hours from the onset of labour until delivery. Infants received 2mg of Zidovudine per kilogram body weight in an oral suspension every six hours for one week after birth. In accordance with national guidelines, if the mother had received Zidovudine for a period of less than 4 weeks, the infant was treated for 4 to 6 weeks after birth.
Nevirapine-Nevirapine group: standard Zidovudine prophylaxis + single oral dose of Nevirapine (200mg) at onset of labour and baby received Nevirapine oral suspension 6mg fixed dose) between 48 and 72 hours after birth.
Nevirapine-Placebo group: standard Zidovudine prophylaxis + single oral dose of Nevirapine (200mg) at onset of labour and baby receives placebo between 48 and 72 hours after birth.
Placebo-Placebo group: standard Zidovudine prophylaxis + placebo at onset of labour and baby receives placebo between 48 and 72 hours after birth.
OUTCOMES
Primary: Infection with HIV in infants (positive PCR test in blood samples obtained on two separate occasions, after 1 month of age). Adverse events. Safety and efficacy of Nevirapine administered perinatally together with standard Zidovudine prophylaxis.
Secondary: Evaluate the effect of the administration of perinatal Nevirapine to newborns (N-N group vs N-P group in final analysis).
RISK OF BIAS
(Risk Scale: Low -Moderate -High)
SELECTION BIAS: Low
Study drugs were identified by random numbers with the use of permuted blocks of six in a ration of 1:1:1. Women were randomly assigned to groups. No mention of allocation concealment. Baseline characteristics of women, deliveries and the newborn were similar across groups.
PERFORMANCE BIAS: Low
It appeared that both the patient and the provider were blinded to the treatment being provided.
DETECTION BIAS: Low-moderate
Safety assessment was conducted by persons blinded to treatment assignment. Not clear whether or not other assessors were blinded.
ATTRITION BIAS: Low
A similar number of individuals (~10%) were lost to follow-up/still birth or unable to be evaluated from the three treatments. An "as-randomised analysis and pre-protocol analysis was performed". 
ADVERSE EVENTS
Mother: No severe rashes observed. At day 10, mild rashes were observed in 3.8 percent of mothers. Rates of serious adverse events similar across the groups -relating to pregnancy = 59%, infection or HIV = 26%, possibly Zidovudine prophylaxis (i.e. anaemia) = 7%, possibly Nevirapine (allergic reaction during therapy) = 7% out of total 216 total reported incidents.
